SAN DIEGO, April 20, 2011 – Profil™ Institute for Clinical Research, Inc., a company leading the industry in early phase clinical trials for diabetes and obesity, announced today its sponsorship of the American Diabetes Association’s Tour de Cure, an annual nationally recognized cycling event on Saturday, May 7 in Cardiff By The Sea.
The Tour de Cure, a fund-raising event with cyclists participating in routes of 10 to 100 miles, attracted 50,000 cyclists in 80 Tour events and raised nearly $17 million last year. Funds raised are used to support the mission of the American Diabetes Association: to prevent and cure diabetes and to improve the lives of all people affected by the disease.
In conjunction with Profil Institute’s sponsorship of the Tour de Cure, many of the company’s employees participate in the event as a team and each individually raise money. Profil Institute’s CFO Claus Hakenesch is also San Diego’s 2011 Public Relations Committee Chairperson for the event.
“Each year, we at Profil Institute get very excited about this event. The Tour de Cure is our opportunity to sponsor, volunteer for and participate in a local event benefiting the American Diabetes Association and the very patients that we work with for our clinical trials,” said Profil Institute’s CEO Dr. Marcus Hompesch. “Each of our employees finds a way to support this event whether through individually raising funds, participating in or volunteering. As a company we couldn’t be more pleased to sponsor the Tour de Cure.”
For more information about San Diego’s Tour de Cure to take place on Saturday, May 7, 2011, visit the website:
http://main.diabetes.org/site/TR/TourdeCure/SanDiegoArea.
About Profil™ Institute for Clinical Research, Inc.
Profil Institute is world-renowned as a Center of Excellence for diabetes and obesity early phase clinical research. The company’s advances in early phase drug research and its specific focus on diabetes, obesity and cardio-metabolic diseases as it relates to the diabetic patient population have led Profil Institute to be the most highly regarded clinical research institute for early phase diabetes drug trials.
To date, Profil Institute has been involved with almost every clinically promising drug category and device development in diabetes and in more than 140 clinical studies since the company’s inception in 2004. Contributing to Profil Institute’s success is that the company is recognized as the leader in automated glucose clamps, considered the “Gold Standard” for the evaluation of anti-diabetic drugs and devices. The company’s key scientists hail from academic centers including the WHO Collaborating Center of Diabetes at the Heinrich-Heine University of Düsseldorf, Columbia University, University of Michigan and Harvard University.
For more information visit www.profilinstitute.com.
For further information please contact:
Abigail Devine
Corporate Communications
adevine@irprsolutions.com
858-663-6148 cell
